General presentation of BioNTech
We shall now examine the BioNTech Group in more detail together with its activities. In fact, a comprehensive knowledge of the precise activities of this company is necessary for you to understand how it can evolve and grow and how its share price could react over the medium or long term. Here therefore is a complete presentation of this group, its activities, and major sources of revenue.
The BioNTech SE Company is a German group that exercises its activities in the biotechnological sector. More precisely this company that is based in Germany concentrates its activities in the immunotherapy segment specifically for the treatment of cancer and other serious illnesses.
This biotech company has therefore developed a wide range of products that use scientific approaches and technological platforms notably including individual product candidates based on the mRNA, chimeric antigen T cell receptors, control immunomodulators, targeted cancer antibodies and small molecules.
It should also be noted that this company offers a large range of diagnostic products and exploratory medicinal services in other therapeutic sectors such as for example infectious diseases, allergies and auto-immune illnesses.
The popularity of the BioNTech Company was recently boosted in 2020 by the implementation of a partnership with the American laboratory Pfizer for the development of the first anti-covid vaccine that received approval and that uses BioNTech’s RNA messenger technology.
The BioNTech Group currently employs around 1,300 people worldwide.
72% of retail investor accounts lose money when trading CFDs with this provider. This is an advert for trading CFDs on Plus500